tbuckley/cabot-search huggingface dataset:
Reply to Ashwin Shinde, Richard Li, Arya Amini, and Scott Glaser's Letter to the Editor re: Liselotte M.S. Boevé, Maarten C.C.M. Hulshof, André N. Vis, et al. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial. Eur Urol 2019;75:410–8
Authors: Liselotte M.S. Boevé, Paul C.M.S. Verhagen, André N. Vis
Journal: European Urology (2018)
Leads from the MMWR. Prevalence of oral lesions and smokeless tobacco use in Northern Plains Indians
Journal: JAMA (1989)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
<i>On. Aphasia, or the Lose of Speech, and the Localization of the Faculty of Articulate Language.</i>By Frederick Bateman. M. D., F. R. C. P., etc. Second edition, greatly enlarged. London: J. &amp; A. Churchill. Jarrold &amp; Sons, 3 Paternoster Buildings
Authors: H. S. W.
Journal: American Journal of Psychiatry (1890)
Bioequivalence of 20-mg Once-Daily Tamoxifen Relative to 10-mg Twice-Daily Tamoxifen Regimens for Breast Cancer
Authors: A.U. Buzdar, G.N. Hortobagyi, D. Frye, D. Ho, D.J. Booser, V. Valero, F.A. Holmes, B.K. Birmingham, K. Bui, C. Ye
Journal: Journal of Clinical Oncology (1994)

Table 2 in the report entitled "Bioequivalence of 20-mg Once-Daily Tamoxifen Relative to 10-mg Twice-Daily Tamoxifen Regimens for Breast Cancer" by Buzdar et al contained an error in two column headings. It is reprinted here correctly in its entirety. Please see the PDF for Table.
Abstract 2240: T2-Prepared Steady-State Free-Precession Blood Oxygenation Level-Dependent MRI in Patients with Coronary Artery Disease and Normal Volunteers: Validation against PET
Authors: Theodoros D Karamitsos, Alejandro Recio-Mayoral, Jayanth R Arnold, Lucia Leccisotti, Paul Bhamra-Ariza, Ruairidh K Howells, Nick Searle, Matthew D Robson, Ornella E Rimoldi, Paolo G Camici, Stefan Neubauer, Joseph B Selvanayagam
Journal: Circulation (2008)

Blood oxygenation level-dependent (BOLD) MRI clinical studies at 1.5 Tesla (T) have been principally limited by low signal to noise. We sought to apply this method at 3T in patients with coronary artery disease (CAD) and normal volunteers, and validated it against perfusion measurements by PET. Twenty-two patients (age 62±8 yrs, 16 men) with CAD (at least 1 stenosis &gt; 50% on quantitative coronary angiography-QCA) and 10 normal volunteers (age 52±7 yrs, 7 men) underwent 3T BOLD MRI and PET. For BOLD MRI a mid-ventricular slice was acquired every 30sec at rest and during adenosine stress (140 μg/kg/min). A set of 6 images was acquired at rest and at peak stress. Using PET with oxygen-15 labelled water, myocardial blood flow (MBF) was measured at baseline and during adenosine hyperemia. The BOLD short-axis view was divided into 6 segments, according to the mid-ventricular segments of the 17-AHA segment model, and mean signal intensities (SI) were calculated using QMass (Medis) software. PET images were analyzed with MATLAB software (MathWorks Inc.) and registered with the BOLD short-axis image using anatomical landmarks. Taking QCA as the gold standard, cut-off values for stress MBF (&lt; 2.57ml/min/g - AUC 0.79) and BOLD SI change (&lt; 4.75% -AUC 0.78) were determined to define ischemic segments. Rest MBF, stress MBF, coronary flow reserve and BOLD-SI change of ischemic (n=69), remote to ischemia (n=73) and normal segments (n=60) are shown in table . BOLD MRI and PET agreed on the presence or absence of ischemia in 18 of the 22 patients (82%), and in all normals. With regards to per segment analysis: taking PET as the gold standard and by applying the cut-off values for stress MBF and BOLD SI, BOLD MRI had only moderate sensitivity (61%) but good specificity (88%) for the identification of ischemia. T2-prepared SSFP 3T BOLD imaging is feasible in the clinical setting and has good agreement with PET perfusion measurements for the detection of myocardial ischemia.
Separate analysis of asialoglycoprotein receptors in the right and left hepatic lobes using 99mTc-GSA SPECT
Authors: K Sugahara
Journal: Hepatology (2003)

The asialoglycoprotein receptor (ASGPR) is abundantly expressed on the sinusoidal surfaces of hepatocytes. We aimed to clarify the clinical significance of the regional distribution of ASGPRs in the human liver, especially in chronic viral hepatitis. Eighteen volunteers, 34 patients with chronic hepatitis, and 33 patients with cirrhosis (11/Child-Pugh A, 11/Child-Pugh B, 11/Child-Pugh C) were studied using a newly developed, conventional technetium-99m-diethylenetriaminepentaacetic acid-galactosyl human serum albumin (99mTc-GSA), single photon emission computed tomography (SPECT) method. Using Cantlie's line as a guide, ASGPR dynamics were analyzed separately in the right and left lobes, as well as in the whole liver, using novel indices (the liver uptake ratio [LUR] and the liver uptake density [LUD], which reflect the amount and density of ASGPRs in the liver, respectively). Mean LUR and LUD values for the whole liver and the right and left lobes decreased with increasing progression of chronic viral hepatitis. The LUR for the whole liver correlated well with parameters measuring the hepatic functional reserve and the platelet count. The right LUR correlated particularly well with conventional liver function tests, and comparison of the right LUD with histologic findings showed that it was a good indicator of periportal and/or bridging necrosis and fibrosis. In conclusion, our 99mTc-GSA SPECT method was clinically useful in evaluating regional hepatic function and the progression of chronic viral hepatitis using dynamic changes in ASGPRs. (Hepatology 2003;38:1401-1409.)
Catheterization and Mortality in Elderly Patients With Acute Myocardial Infarction-Reply
Authors: Joseph P. Newhouse
Journal: JAMA (1995)

<h3>In Reply.</h3> —We used empirical data on treatments and outcomes of elderly AMI patients to estimate the mortality consequences of the additional catheterization and revascularization procedures performed by the most intensive hospitals relative to other hospitals. In contrast, Drs Kuller and Detre postulate that invasive procedures prevent death in 1 year in a substantial portion (one fourth) of the 26.2% of patients who received them. Further, their claim that randomized trials can answer this question is inaccurate. Under ideal circumstances, a standard randomized controlled trial estimates the average effect of treatment over an entire study population. Because we suspect that invasive procedures are highly effective in certain kinds of elderly AMI patients and ineffective in others, we instead sought to estimate the average effect on mortality for "incremental" changes in use of these procedures within the population of elderly AMI patients. A more complete discussion of the differences between population
Pharmacologic Aspects of Adrenocortical Steroids and ACTH in Man
Authors: George W. Thorn, Dalton Jenkins, John C. Laidlaw, Frederick C. Goetz, Joseph F. Dingman, Walter L. Arons, David H. P. Streeten, Brian H. McCracken
Journal: New England Journal of Medicine (1953)

Effects of cortisone on endocrine system. Anterior pituitary body and adrenal glands: It is well known that the administration of cortisone to animals and man leads to a suppression of endogenous adrenocortical secretion. Several lines of evidence may be cited. Patients, both male and female, with an intact pituitary-adrenal system may show a decreased urinary 17-ketosteroid output during cortisone therapy (50 to 75 mg. a day). After cortisone administration ACTH may elicit a poor adrenal response as measured by eosinophil fall, and 17-ketosteroid and formaldehydogenic steroid rise in the urine. When cortisone therapy is suddenly withdrawn clinical evidences of adrenal . . .
Use of Novel Combination Therapies in the Treatment of Advanced HR+/HER2− Breast Cancer
Authors: Ruth O'regan
Journal: Journal of the National Comprehensive Cancer Network (2018)

Endocrine therapy remains the backbone for treatment of hormone receptor-positive breast cancer in the metastatic setting. Despite the effectiveness of endocrine therapy, primary and acquired endocrine resistance continue to be important clinical challenges. The landscape of metastatic breast cancer treatment has changed considerably with the incorporation of novel agents, including cyclin-dependent kinase 4/6 and mammalian target of rapamycin inhibitors. This article reviews current endocrine treatment strategies and recent and ongoing studies of combination therapies in metastatic hormone receptor-positive, HER2-negative breast cancer.
High plasma levels of von Willebrand factor as a marker of endothelial perturbation in cirrhosis: Relationship to endotoxemia
Authors: D Ferro
Journal: Hepatology (1996)

The aim of this study was to evaluate whether there is endothelial dysfunction in patients with cirrhosis and to detect the mechanism that may account for it. We measured plasma levels of von Willebrand factor (vWF), a marker of endothelial perturbation, and endotoxin, which releases vWF from endothelial cells in vitro, in 32 patients (18 men, 14 women, aged 39-70 years) with cirrhosis classified as mild (class A, n = 10), moderate (class B, n = 16), or severe (class C, n = 6) according to Child-Pugh's classification. vWF antigen (P < .0001) and endotoxemia (ρ < .0001) progressively increased from A to class C; but the increase of vWF antigen was not strictly related to liver failure, as shown by the lack of correlation between vWF and several indexes of liver protein synthesis. Analysis of the vWF subunit showed no sign of proteolytic fragmentation of the molecule. Multimeric analysis indicated intact vWF multimeric structure. In all patients, there was a strong correlation between vWF antigen and endotoxemia (rho = .92; P = .0001). In 20 selected patients, vWF antigen and endotoxemia were measured before and after 7 days of standard therapy (n = 10) or standard therapy plus nonabsorbable antibiotics. There was a significant decrease of vWF antigen (P < .02) concomitantly with the decrease of endotoxemia (P < .006) in patients taking nonabsorbable antibiotics. Human umbilical vein endothelial cells incubated in vitro with 125 to 500 pg/mL endotoxin released vWF antigen into the medium dose dependently. These results demonstrate that there is endothelial perturbation in cirrhosis and that endotoxemia may play a key role in its occurrence.
The evolution, implications, and applications of the hepatitis B vaccine
Authors: H. J. Alter
Journal: JAMA (1982)

The Centers for Disease Control (CDC) estimates that there are 200,000 new cases of hepatitis B virus (HBV) infection annually in the United States. Approximately 25% of patients have overt disease and about 10,000 require hospitalization; 1% to 2% of those hospitalized die during the acute phase of their disease. Of those infected, 5% to 10% (10,000 to 20,000 per year) become chronic HBV carriers, adding to the approximately 800,000 hepatitis B carriers in the United States alone. Among these carriers, cirrhosis or hepatocellular carcinoma will develop in some; HBV infection is a major cause of nonalcoholic cirrhosis, and the CDC estimates that there are almost 4,000 deaths per year from cirrhosis among chronic HBV carriers. It has also been estimated that hepatitis B, in terms of hospitalization, other medical expenses, and time lost from work, costs the US economy $750 million per year. Recognizing that the United States is
Differences in the Pathways for Metabolism of Benzene in Rats and Mice Simulated by a Physiological Model
Authors: Michele A. Medinsky, Patrick J. Sabourin, Rogene F. Henderson, George Lucier, Linda S. Birnbaum
Journal: Environmental Health Perspectives (1989)

Studies conducted by the National Toxicology Program on the chronic toxicity of benzene indicated that B6C3F1 mice were more sensitive to the carcinogenic effects of benzene than were F344 rats. A physiological model was developed to describe the uptake and metabolism of benzene in rats and mice. Our objective was to determine if differences in toxic effects could be explained by differences in pathways for benzene metabolism or by differences in total uptake of benzene. Compartments incorporated into the model included liver, fat, a poorly perfused tissue group, a richly perfused tissue group, an alveolar or lung compartment and blood. Metabolism of benzene was assumed to take place only in the liver and to proceed by four major competing pathways. These included formation of hydroquinone conjugates (HQC), formation of phenyl conjugates (PHC), ring-breakage and formation of muconic acid (MUC), and conjugation with glutathione with subsequent mercapturic acid (PMA) formation. Values for parameters such as alveolar ventilation, cardiac output, organ volumes, blood flow, partition coefficients, and metabolic rate constants were taken from the literature. Model simulations confirmed that during and after 6-hr inhalation exposures mice metabolized more benzene on a mumole per kilogram body weight basis than did rats. After oral exposure, rats metabolized more benzene than mice at doses above 50 mg/kg because of the more rapid absorption and exhalation of benzene by mice. Model simulations for PHC and PMA, generally considered to be detoxification metabolites, were similar in shape and dose-response to those for total metabolism.(ABSTRACT TRUNCATED AT 250 WORDS)
Elements of Pharmacy, Materia Medica, and Therapeutics.
Journal: JAMA (1884)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Common bony densities simulating disease in the chest
Authors: C. L. Chiu
Journal: JAMA (1975)

FREQUENTLY encountered on chest roentgenograms are variations or shadows of normal structures projected in such a way that pathologic processes are simulated. Certain benign processes may also produce shadows that mimic those of malignant lesions. Keeping the possibility of such simulated disease in mind enables the viewer to recognize more easily the true nature of such images, with resultant facilitation of patient care. With this in mind, a few common examples are presented for illustration. An ill-defined nodular density is seen through the shadow of the right side of the heart on frontal projection and overlies the spine on lateral view (Fig 1, left). An open arrow (Fig 1, center) indicates a second such density on the lateral view slightly above and anterior to the first. The possibility of pulmonary nodules was raised, and conventional tomography was performed for further evaluation of the lesions. This was not very helpful, showing
PIPERAZINE IN GOUT.
Journal: JAMA (1992)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Reye's Syndrome and Salicylates
Authors: Joseph M. White
Journal: JAMA (1987)

<h3>To the Editor.—</h3> The accusations against the federal regulatory authorities and the pharmaceutical industry contained in the editorial by Dr Mortimer<sup>1</sup>entitled "Reye's Syndrome, Salicylates, Epidemiology, and Public Health Policy" are inconsistent with the facts. The editorial is unfair not only to the Food and Drug Administration (FDA) and the industry, but to the many physicians and scientists who in 1982 and 1983 recognized the serious flaws in the early Reye's syndrome surveys and who advocated that public health decisions be based on sound scientific studies. Dr Mortimer states that "the first reasonably conclusive evidence of an association and a tentative warning appeared in 1980, but no definitive action was taken until 1986." He is wrong on both counts. The evidence in 1980 was far from conclusive. Nearly all public interest and academic commentators at the time, including the American Medical Association (AMA) and the American Academy of Pediatrics,
A phase II study of 3-week scheduling of irinotecan (I) in combination with cisplatin (P) (revised-IP) in patients with stage IIIB or IV non-small cell lung cancer (NSCLC)
Authors: H. Saito, S. Kudoh, K. Nakagawa, S. Negoro, K. Matsui, H. Senba, S. Tsukiyama, M. Takada
Journal: Journal of Clinical Oncology (2004)

7284
Woman as a Sexual Criminal
Journal: JAMA (1934)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Book Reviews
Authors: S. E. KANE
Journal: JNCI Journal of the National Cancer Institute (1988)

Book Reviews Get access Gene Clonging and Analysis: A Laboratory Guide. G. J. Boulnois, ed. Palo Alto, CA: Blackwell, 1987, 136 pp. $32.50. SUSAN E. KANE SUSAN E. KANE Laboratory of Molecular Biology National Cancer InstituteBldg. 37, Rm. 2D19 National Institutes of Health Bethesda, MD 20892 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 80, Issue 11, 3 August 1988, Pages 872–873, https://doi.org/10.1093/jnci/80.11.872 Published: 03 August 1988
Heterogeneity of Thalassemia Major
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Reporting results from chemotherapy trials. Does response make a difference in patient survival?
Authors: R. K. Oye
Journal: JAMA (1984)

Patients with many common tumors are treated with chemotherapy despite limited evidence of treatment effectiveness. To determine if chemotherapy trials reporting effectiveness actually demonstrated increased survival in treated patients, we reviewed trials published over a two-year period involving four common solid tumors. Of 80 studies, 95% reported response to chemotherapy as an end point. Of 38 studies demonstrating 15% or greater objective response, 76% reported significantly greater survival of responders than of nonresponders. Of 21 studies containing statements supporting treatment effectiveness, 95% based this claim at least in part on the superior survival of responders compared with nonresponders. Because responders may have lived longer without treatment, such comparisons are not valid and may lead to overly optimistic views of chemotherapy effectiveness. Journal editors should be wary of allowing survival comparisons between responders and nonresponders in published reports. (<i>JAMA</i>1984;252:2722-2725)